Skip to main content
Top
Published in: Medical Oncology 1/2015

01-01-2015 | Review Article

Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case–control studies

Authors: Qing Li, Liu Liu, Yanling Liu, Huirong Zhou, Zhi Yang, Keng Yuan, Weiping Min

Published in: Medical Oncology | Issue 1/2015

Login to get access

Abstract

The correlationship between COX-2 gene polymorphisms and breast cancer has been wildly studied, but the results remain controversial. Hence, the present meta-analysis aimed to investigate the association between COX-2 SNPs (rs5275, rs20417, rs689466, rs5277, rs2206593) and risk of breast cancer. Data were collected from PubMed, Embase and China National Knowledge Infrastructure. Summary odds ratio (OR) with 95 % confidence interval (CI) was applied to assess the relationship. Heterogeneity test, sensitivity analysis and publication bias test were also performed. There were 17 articles that contained 19 studies in this research. Fourteen case–control studies with 15,007 breast cancer cases and 20,005 controls were concerning rs5275 polymorphism, and 8 case–control studies with 10,216 cases and 12,839 controls were about rs20417 polymorphism. Other three polymorphisms (rs689466, rs2206593, rs5277) were studied in 5, 3 and 3 studies, respectively. COX-2-rs20417 CC genotype was significantly associated with increased risk of breast cancer when comparing to G allele [ORs were 1.231 (1.050–1.444) for CC vs. GG, P = 0.01, 1.223 (1.045–1.432) for CC vs. G carrier, P = 0.01]. Furthermore, the results of the subgroup analysis by ethnicity suggested that C allele significantly contributed to the risk of breast cancer for Asians [1.459 (1.182–1.802) for GC vs. GG, 1.472 (1.201–1.805) for C carrier vs. GG]. However, no association was found for rs5275, rs689466, rs5277 and rs2206593 in all comparison modes. This meta-analysis indicated that the COX-2 rs20417 polymorphism contributed to genetic susceptibility of breast cancer. In contrast, COX-2 rs5275, rs689466, rs2206593 and rs5277 polymorphisms might be not associated with the risk of breast cancer.
Literature
1.
go back to reference Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res. 2004;43:3–35.PubMedCrossRef Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res. 2004;43:3–35.PubMedCrossRef
3.
go back to reference Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed
6.
go back to reference Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–80.PubMed Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–80.PubMed
7.
go back to reference Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997–5001.PubMed Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997–5001.PubMed
8.
go back to reference Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.PubMed Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.PubMed
9.
go back to reference Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7:1163–70.PubMedCrossRef Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7:1163–70.PubMedCrossRef
11.
go back to reference Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. I. Women’s Health. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003;63:6096–101.PubMed Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. I. Women’s Health. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003;63:6096–101.PubMed
12.
13.
go back to reference Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–5.PubMed Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–5.PubMed
14.
go back to reference Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31:455–61. doi:10.1093/carcin/bgp307.PubMedCentralPubMedCrossRef Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31:455–61. doi:10.​1093/​carcin/​bgp307.PubMedCentralPubMedCrossRef
15.
go back to reference Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res. 2006;12:1392–4. doi:10.1158/1078-0432.CCR-05-2055.PubMedCrossRef Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res. 2006;12:1392–4. doi:10.​1158/​1078-0432.​CCR-05-2055.PubMedCrossRef
18.
go back to reference Gao J, Kang HF, Ma XB, Tang W, Liu D, Zhao Y, Zhang SQ, Guan HT, Lin S, Ren HT, Wang XJ, Dai ZJ. Functional promoter-765 G>C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women. Cancer Cell Int. 2014;14:38. doi:10.1186/1475-2867-14-38.PubMedCentralPubMedCrossRef Gao J, Kang HF, Ma XB, Tang W, Liu D, Zhao Y, Zhang SQ, Guan HT, Lin S, Ren HT, Wang XJ, Dai ZJ. Functional promoter-765 G>C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women. Cancer Cell Int. 2014;14:38. doi:10.​1186/​1475-2867-14-38.PubMedCentralPubMedCrossRef
19.
go back to reference Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8:R71. doi:10.1186/bcr1629.PubMedCentralPubMedCrossRef Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8:R71. doi:10.​1186/​bcr1629.PubMedCentralPubMedCrossRef
20.
go back to reference Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, Freudenheim JL. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2011;126:157–65. doi:10.1007/s10549-010-1082-x.PubMedCentralPubMedCrossRef Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, Freudenheim JL. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2011;126:157–65. doi:10.​1007/​s10549-010-1082-x.PubMedCentralPubMedCrossRef
21.
go back to reference Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443–52. doi:10.1002/cncr.21763.PubMedCrossRef Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443–52. doi:10.​1002/​cncr.​21763.PubMedCrossRef
22.
go back to reference Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case–control study. Breast Cancer Res. 2007;9:R3. doi:10.1186/bcr1635.PubMedCentralPubMedCrossRef Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case–control study. Breast Cancer Res. 2007;9:R3. doi:10.​1186/​bcr1635.PubMedCentralPubMedCrossRef
23.
go back to reference Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, Pharoah PD. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res. 2009;15:2181–91. doi:10.1158/1078-0432.CCR-08-0716.PubMedCrossRef Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, Pharoah PD. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res. 2009;15:2181–91. doi:10.​1158/​1078-0432.​CCR-08-0716.PubMedCrossRef
24.
go back to reference Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007;28:427–34. doi:10.1093/carcin/bgl170.PubMedCrossRef Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007;28:427–34. doi:10.​1093/​carcin/​bgl170.PubMedCrossRef
25.
go back to reference Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, Jin GF, Liu JY, Tan YF, Wang XR, Shen HB. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health Part A. 2007;70:908–15. doi:10.1080/15287390701289966.PubMedCrossRef Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, Jin GF, Liu JY, Tan YF, Wang XR, Shen HB. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health Part A. 2007;70:908–15. doi:10.​1080/​1528739070128996​6.PubMedCrossRef
26.
go back to reference Ahmadi B, Nikzamir A, Ghafari SM, Mohamadzadeh G, Latifi M, Bafandeh A, Fathi M, Yekaninejad MS, Nikzamir M. Lack of association between cyclooxygenase 2-765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran. Mol Biol Rep. 2014;41:997–1001. doi:10.1007/s11033-013-2944-1.PubMedCrossRef Ahmadi B, Nikzamir A, Ghafari SM, Mohamadzadeh G, Latifi M, Bafandeh A, Fathi M, Yekaninejad MS, Nikzamir M. Lack of association between cyclooxygenase 2-765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran. Mol Biol Rep. 2014;41:997–1001. doi:10.​1007/​s11033-013-2944-1.PubMedCrossRef
29.
go back to reference Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM. Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:251–7. doi:10.1007/s10549-009-0688-3.PubMedCrossRef Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM. Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:251–7. doi:10.​1007/​s10549-009-0688-3.PubMedCrossRef
31.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
32.
35.
go back to reference Dai Z-J, Shao Y-P, Ma X-B, Xu D, Tang W, Kang H-F, Lin S, Wang M, Ren H-T, Wang X-J. Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects. Dis Mark. 2014;1–9:2014. doi:10.1155/2014/484729. Dai Z-J, Shao Y-P, Ma X-B, Xu D, Tang W, Kang H-F, Lin S, Wang M, Ren H-T, Wang X-J. Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects. Dis Mark. 2014;1–9:2014. doi:10.​1155/​2014/​484729.
36.
go back to reference Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem. 2001;276:23179–85. doi:10.1074/jbc.M008461200.PubMedCrossRef Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem. 2001;276:23179–85. doi:10.​1074/​jbc.​M008461200.PubMedCrossRef
Metadata
Title
Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case–control studies
Authors
Qing Li
Liu Liu
Yanling Liu
Huirong Zhou
Zhi Yang
Keng Yuan
Weiping Min
Publication date
01-01-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0397-6

Other articles of this Issue 1/2015

Medical Oncology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.